FISH

Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics

Retrieved on: 
Wednesday, April 3, 2024
Sarcoma, Diagnosis, KT, Oncogene, SAN, Neoplasm, Research, Cancer, Doctor of Philosophy, CDKN2A, Workflow, Karyotype, FISH, Genomics, Chromothripsis, SVS, Prognosis, Aberration, OGM, Medical imaging

Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.

Key Points: 
  • Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.
  • The detection of SVs and CNVs remains challenging and typically requires multiple traditional cytogenetic techniques.
  • In this study, researchers demonstrated OGM’s ability to detect aberrations as small as 500 bp, which is approximately 10,000-fold higher resolution than that of KT.
  • As shown in this study, OGM can provide better characterization of the genomic complexity of sarcoma samples when compared to traditional cytogenetic techniques, due to the workflow’s high resolution and ​comprehensive, genome-wide analysis.

STEMCELL Technologies Announces FDA De Novo Classification for Its EasySep™ CD138 Positive Selection Kit to Support Cancer Diagnostic Tests

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, FDA, Medical Devices, Clinical Trials, Pharmaceutical, Biotechnology, De novo, Stemcell Technologies, Plasma, In situ hybridization, Medicine, Cell, Bone marrow, Partnership, Risk, Patient, Fluorescence, Sale, Classification, Multiple myeloma, DSM-IV codes, B cell, IVD, National Comprehensive Cancer Network, American College, European, FISH, Cancer, CD138, Multimedia, Food, Medical device

STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.

Key Points: 
  • STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.
  • View the full release here: https://www.businesswire.com/news/home/20240326396951/en/
    STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit is now classified by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.
  • (Photo: Business Wire)
    The kit can be used to enrich plasma cells expressing the CD138 marker (CD138+ cells) from patient bone marrow samples.
  • The EasySep™ Human Bone Marrow CD138 Positive Selection Kit will be available for sale in the United States, the European Union, Canada, and the United Kingdom.

Fish Head Farms, Inc. Announces Exclusive Distribution and Sales Agreement With D&K Products, Inc.

Retrieved on: 
Wednesday, March 20, 2024
Environment, Sports, Marketing, Golf, Communications, Fishing, Alternative Medicine, Health, Agriculture, Natural Resources, USDA, OMRI, Nutrient, NPK, CDFA, Germination, FISH, Soil, CFIA

Today, Fish Head Farms, Inc is announcing an exclusive sales, marketing, and distribution agreement with D&K Products, Inc, for FISH SH!T.

Key Points: 
  • Today, Fish Head Farms, Inc is announcing an exclusive sales, marketing, and distribution agreement with D&K Products, Inc, for FISH SH!T.
  • The agreement between the companies is for the golf and turf markets in Iowa, Nebraska, and Western Illinois.
  • Fish Head Farms manufactures, markets, and distributes FISH SH!T, the most robust beneficial bacteria product available for use in the Agricultural, Golf Course Maintenance, Cannabis and Plant Industries.
  • Joe Blanchard, Fish Head Farms Chief Revenue Officer, said “We are thrilled to partner with D&K Products.

Bionano’s Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS

Retrieved on: 
Tuesday, January 30, 2024
SAN, Breast, University, International, MD Anderson Cancer Center, FACMG, FDA, VAF, Bone marrow, SVS, Cytogenetics, Genome, LRS, OGM, University of Toronto, TNBC, Pressure, Biomarker, PARP, Quality control, Karyotype, HRD, Saint John Regional Hospital, T-ALL, CRISPR, Curie Institute, Triple-negative breast cancer, In situ hybridization, FISH, Frog, Genomics, Hospital, HRP, Patient, Marfan syndrome, Fluorescence, NIST, DSM-IV codes, Doctor of Philosophy, Cancer, Multiple myeloma, Workflow, Gene editing, Research, KT, Cell, Down syndrome, NGS, Vaccine

During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.

Key Points: 
  • During this four-day online event, presenters reported on their use of OGM for applications in cancer, genetic disease, and cell and gene therapy.
  • OGM is helping to unravel persistent, complex mysteries in genetic disease that impact people, even in more common disorders like Down syndrome and Marfan syndrome.
  • OGM has the potential to meet the key requirements of the cell and gene therapy community.
  • “I would encourage anyone who was unable to attend live to login, view these presentations and see how bright the future of cytogenetics is with OGM.”

Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing

Retrieved on: 
Wednesday, January 24, 2024
SAN, Standard of care, Fluorescence, University of Rochester, Test management, University, SVS, FISH, Genomics, DSM-IV codes, In situ hybridization, IRB, SOC, Karyotype, CMA, KT, Columbia University, OGM, Clinical trial, Institutional review board, Data, Diagnosis, Medical device

This publication reports on the prenatal genetic disease clinical trial program to evaluate OGM as an alternative to SOC workflows.

Key Points: 
  • This publication reports on the prenatal genetic disease clinical trial program to evaluate OGM as an alternative to SOC workflows.
  • This second interim readout is designed to evaluate endpoints connected to analytical performance using an expanded dataset in key areas of technical performance and clinical utility of OGM.
  • The study is an Institutional Review Board (IRB)-approved, multicenter, double-blinded trial with samples from 219 unique retrospective (57) and prospective (162) clinical research subjects.
  • All samples had been previously tested with traditional methods including karyotyping (KT), fluorescence in situ hybridization (FISH) and chromosomal microarray (CMA).

Molecular Diagnostics in Oncology, Genetic/Inherited Diseases and NIPT 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 29, 2024
Health, Oncology, ISH, NGS, DSM-IV codes, Research, Molecular diagnostics, IVD, Knowledge, NIPT, Cancer, Woman, Medicine, Risk, FISH, Recurrence, Laboratory, FDA, Biomarker, Diagnosis, PCR, Inherit, Segment, Chromosome, Gene expression, Medical imaging

The "Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • In addition, the fields of rare inherited/ genetic diseases and NIPT have become areas of new breakthroughs in healthcare.
  • These and other technologies and applications in oncology, rare inherited/ genetic disease, and NIPT molecular diagnostic testing are covered in the report.
  • The report contains detailed market data on the following IVD segments for their use in molecular testing:
    Molecular Diagnostics in Oncology Market by Segment, 2023-2028

Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Date of authorisation: 09/02/2018, Revision: 21, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Stomach, INN, Risk, HER2, Breast, Tissue, Heart, Cancer, Neoplasm, Cardiotoxicity, Infection, Anatomy, Paclitaxel, IIA, Breast cancer, ATC, European, Allergy, Metastasis, Blood, Capecitabine, MBC, EBC, Safety, Heart failure, MGC, Patient, Medical Subject Headings, Agency, European Commission, Cyclophosphamide, Immune system, Docetaxel, Carboplatin, International, Language, Cisplatin, Select, Enzyme inhibitor, Medicine, FISH, Radiation, Lymph, Arm, European Medicines Agency, Fluorouracil, Doxorubicin, Medical device

Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Date of authorisation: 09/02/2018, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, Date of authorisation: 09/02/2018, Revision: 21, Status: Authorised

Cancers Journal Publishes Special Issue Dedicated to OGM’s Impact on Hematological Malignancy Research

Retrieved on: 
Thursday, December 14, 2023
Editorial, Oncology, In situ hybridization, CMA, OGM, SVS, Radboud University Medical Center, Research, Workflow, Fluorescence, DRS, Bone marrow, SAN, Doctor of Philosophy, Chronic lymphocytic leukemia, Multiple myeloma, Genomics, University, Karyotype, CLL, Cytogenetics, FACMG, Growth, University of Toronto, Publication, Acute myeloid leukemia, KT, AML, FISH

SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow.

Key Points: 
  • SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow.
  • “I personally believe the importance of OGM for hematological malignancies research cannot be overstated.
  • The papers published in this dedicated issue elegantly illustrate how information provided by OGM surpasses the capabilities of the current tools in cancer research.
  • “This special edition of Cancers dedicated to OGM is a significant milestone for the technique and for people in the various fields of genome analysis who are looking for ways to move the community forward.

Pioneer Consulting Selected to Continue Support of the FISH Submarine Cable System in Alaska

Retrieved on: 
Tuesday, December 12, 2023
Pioneer, Internet, Village, Engineering, FISH, Whaling

HOBOKEN, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Pioneer Consulting , the full-service submarine fiber optic telecommunications consulting and project management company, announces it has been selected to provide initial engineering and design services for the FISH in SEAK submarine cable system (Fiber Internet Serving Homes in Southeast Alaska), an early-stage submarine cable which complements the FISH in AK project (Fiber Internet Serving Homes in Alaska).

Key Points: 
  • HOBOKEN, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Pioneer Consulting , the full-service submarine fiber optic telecommunications consulting and project management company, announces it has been selected to provide initial engineering and design services for the FISH in SEAK submarine cable system (Fiber Internet Serving Homes in Southeast Alaska), an early-stage submarine cable which complements the FISH in AK project (Fiber Internet Serving Homes in Alaska).
  • Engineering of a 900 km undersea cable for FISH in SEAK began in fall 2023.
  • The FISH in SEAK and FISH in AK cables will connect at a landing station hub in Cordova, Alaska.
  • "We are thrilled to continue this critical work with the Cordova Telecom Cooperative," said Philip de Guzman, Director of Client Solutions at Pioneer Consulting.

Molecular Cytogenetics Market Size, Share & Trends Analysis Report 2023-2030 - A $4.46 billion by 2030, with CAGR of 10.6% from 2023 to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 28, 2023
Biotechnology, Pharmaceutical, Oncology, Health, Infectious Diseases, Hospitals, Genetics, Clinical Trials, AIR, NGS, Down syndrome, WHO, Cystic fibrosis, Incidence, Thermo Fisher Scientific, DSM-IV codes, Personalized medicine, USD, Knowledge, COVID-19, Public, Cytogenetics, Genomics, CGH, Growth, FISH

The global molecular cytogenetics market size is anticipated to reach USD 4.46 billion by 2030.

Key Points: 
  • The global molecular cytogenetics market size is anticipated to reach USD 4.46 billion by 2030.
  • The market is expected to expand at a CAGR of 10.6% from 2023 to 2030.
  • Thus, the high incidence of diagnostic testing during the pandemic has fueled the growth of the market for molecular cytogenetics.
  • Moreover, rising strategic initiatives by operating players for technological advancements in cytogenetic tools are projected to propel the market for molecular cytogenetics.